APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases
Paula Perez‐Corredor, Timothy E. Vanderleest, Guido N. Vacano, Justin S. Sanchez, Nelson David Villalba‐Moreno, Claudia Mariño, Susanne Krasemann, Miguel Mendivil‐Perez, David Aguillón, Marlene Jiménez-Del-Río, Ana Baena, Diego Sepúlveda‐Falla, Francisco Lopera, Yakeel T. Quiroz, Joseph F. Arboleda‐Velásquez, Randall C. Mazzarino
Abstract
A patient with the PSEN1 E280A mutation and homozygous for APOE3 Christchurch ( APOE3Ch ) displayed extreme resistance to Alzheimer’s disease (AD) cognitive decline and tauopathy, despite having a high amyloid burden. To further investigate the differences in biological processes attributed to APOE3Ch , we generated induced pluripotent stem (iPS) cell-derived cerebral organoids from this resistant case and a non-protected control, using CRISPR/Cas9 gene editing to modulate APOE3Ch expression. In the APOE3Ch cerebral organoids, we observed a protective pattern from early tau phosphorylation. ScRNA sequencing revealed regulation of Cadherin and Wnt signaling pathways by APOE3Ch , with immunostaining indicating elevated β-catenin protein levels. Further in vitro reporter assays unexpectedly demonstrated that ApoE3Ch functions as a Wnt3a signaling enhancer. This work uncovered a neomorphic molecular mechanism of protection of ApoE3 Christchurch, which may serve as the foundation for the future development of protected case-inspired therapeutics targeting AD and tauopathies.